Top 5 Benefits of Cannabis for Alzheimer’s Disease

An elderly couple hugging and smiling

Alzheimer’s Disease is a progressive neurodegenerative disease that typically presents itself in adults over the age of 65. The disease causes symptoms such as dementia; as it progresses, it renders the sufferer increasingly unable to care for themselves. There is no cure for Alzheimer’s, but medications such as cannabis may slow its progression.

1. CBD & THC could help prevent progression of Alzheimer’s and reduce cognitive decline

The biochemistry of human neural networks is vastly complex and not yet fully understood. However, it’s thought that maintaining healthy brain tissue throughout one’s life can significantly reduce the chances of developing neurodegenerative diseases such as Alzheimer’s in old age, or at least slow the onset of such diseases by reducing the rate of cognitive decline.

Regular physical and mental exercise is believed to be vitally important to maintaining neural health, and is arguably the most healthy and effective method of doing so. However, the balance of chemicals in the brain may also be improved by utilizing certain exogenous compounds such as those contained within cannabis.

A chemical formula of CBD against the cannabis leaves background

Cannabis contains various compounds known as cannabinoids, which are structurally similar and have varying effects on brain function and metabolism. Of these, arguably the most important are THC and CBD, which have a range of physiological effects relevant to Alzheimer’s. They can reduce inflammation, act as antioxidants and neuroprotectants, and even stimulate the growth of new neural tissue.

So if taken regularly, there is evidence that they can not only slow the progression of existing Alzheimer’s cases but also slow the onset of new cases.

2. Low doses of THC may help decrease beta amyloid production

The term ‘amyloid beta’ refers to peptides created by the enzymatic fragmentation of amyloid precursor protein, a substance that is fundamentally involved in the regulation of synapse formation and neural plasticity. The precise primary function of amyloid precursor protein (APP) is unknown, and our comprehension of the normal functions of amyloid beta is in its infancy.

However, it’s clear that in individuals suffering from Alzheimer’s, excess amyloid beta accumulates in the brain and aggregates to form amyloid plaques, which are toxic to neural tissue.

A study published in 2014 by researchers at the University of South Florida, USA investigated the relationship between the endocannabinoid system and the process of plaque production. It demonstrated that APP cells incubated with THC at very low doses produced amyloid beta at a slower than normal rate. The THC directly interacted with beta amyloid peptide and inhibited its aggregation into plaques.

The study also showed that THC at low doses reduced levels of glycogen synthase kinase 3 beta (GSK3ß). GSK3ß is an enzyme that’s  normally involved in energy metabolism and neuronal cell development, but is also responsible for the development of neurofibrillary tangles in the brains of Alzheimer’s patients. These neurofibrillary tangles are comprised of tau proteins, particularly paired helical filament tau (PHF-Tau); GSK3ß is believed to be responsible for the production of PHF-Tau.

Healthy and Alzheimer’s brain against the black background

3. Cannabis is anti-inflammatory – Inflammation is heavily linked to Alzheimer’s

Inflammation of neural tissue is increasingly thought to play a major role in the development of Alzheimer’s and other neurodegenerative diseases such as multiple sclerosis and Parkinson’s disease. It’s thought that acute inflammation that initially occurs as a defence mechanism may lead to an uncontrolled chain reaction resulting in chronic inflammation and neuronal deterioration.

Thus, various anti-inflammatory drugs have been investigated as possible treatments for conditions such as Alzheimer’s.

Animation of a healthy brain tissue

Several recent studies have investigated the relationship between the endocannabinoid system and the regulation of neuroinflammation. A study published in 2009 found that the brains of deceased Alzheimer’s patients show noticeable alterations to components of the endocannabinoid system, including increased expression of cannabinoid receptors type I & II in the microglia (the principle immune cells of the central nervous system). This suggests either that a dysfunctional EC system has a role to play in the development of Alzheimer’s or that the progression of Alzheimer’s causes the EC system to become altered.

It appears that in Alzheimer’s, the microglia surround the amyloid plaques in an attempt to destroy amyloid beta clusters through phagocytosis (“eating” the unwanted tissue). However, the rapid production of amyloid beta overwhelms the microglia, keeping them in a constant state of activation that causes them to produce excess inflammatory compounds such as interleukin.

Exactly what modulatory role the cannabinoid receptors play in this scenario is yet to be proven for sure, and determining the precise mechanism will enable the development of treatments that target the microglial receptors and control inflammation at its source.

4. Cannabis is an antioxidant/neuroprotectant that can help protect cells

Oxidative stress and the release of reactive oxygen species is a key component of diseases such as Alzheimer’s, and is inherently associated with immune inflammation. When inflammation occurs, it induces oxidative stress, reduces the antioxidant capacity of cells, and causes the production of free radicals such as reactive oxygen species, which in turn react with fatty acids and proteins in the cell membranes.

The presence of amyloid beta also causes an increase in reactive oxygen species in surrounding cells through interactions with the cell membranes. Ultimately, this contributes to loss of neurons and synapses in the brain, leading to impaired memory and a range of other neurological symptoms.

Again, the role of the EC system in modulating the processes of oxidative stress is not fully understood. But it has been demonstrated repeatedly that administration of cannabinoids can help reduce its effects and can provide a neuroprotective effect on the neurons, slowing the rate of oxidative cell death.

In 2004, a study demonstrated that exposing cells to amyloid beta caused a significant decline in cell survival, but that treating the cells with cannabidiol prior to amyloid beta exposure caused a notable increase in cell survival.

5. Cannabidiol (CBD) stimulates neurogenesis

As well as reducing inflammation and mediating the effects of oxidative stress, cannabidiol is also thought to promote the growth of new neural tissue (a process known as neurogenesis).

In Alzheimer’s, the rapid destruction of neural tissue causes devastating neurological effects and the normal processes of neurogenesis are interrupted by the presence of amyloid beta. Developing therapies that can stimulate neurogenesis may therefore slow the progression of the disease or even reverse its symptoms to some extent.

A 2011 study on Alzheimer’s demonstrated that cannabidiol exerted its anti-inflammatory and antioxidant effects via a mechanism that is independent of the EC system. Instead, it works on a receptor known as the peroxisome proliferator-activated receptor-γ (PPARγ).

By working on the PPARγ, cannabidiol was able to reduce inflammation and production of reactive oxygen species to protect existing cells. Even more, it was able to induce neurogenesis in the hippocampus (a region of the brain that is heavily affected by Alzheimer’s) by directly blocking the action of amyloid beta.

Animation of hippocampal neurons

We still have much to learn of the complex processes that cause Alzheimer’s and related neurodegenerative conditions. But with what we know about the role the endocannabinoid system plays in the maintenance of neural health, there is hope. Let’s hope that new research allows the range of preventative and curative effects of medicinal cannabis to reach those who can benefit.

  • Disclaimer:
    This article is not a substitute for professional medical advice, diagnosis, or treatment. Always consult with your doctor or other licensed medical professional. Do not delay seeking medical advice or disregard medical advice due to something you have read on this website.


11 thoughts on “Top 5 Benefits of Cannabis for Alzheimer’s Disease”

  1. My Husband has alzheimers. He is only 61. We started the cannibas oil and he seems to feel differant, not so confused can draw a clock which he did backwards previously for the doctor. He can add numbers which he could’t before. We are noticing things he can do now. The only thing we have done differantly is taken the cannibas oil.

    1. Scarlet Palmer - Sensi Seeds

      Hi Joanie,

      Thank you for sharing your story with us. It’s always wonderful to hear this kind of result, and I wish you and your husband many more years of health and happiness!

      With best wishes,


  2. We just discovered the CBD tablets ease agitation and wandering in our 92 year old mother with Alzheimers, who lives with us!
    – Jean

  3. The mind and it’s hardware the brain in this case is a terrible thing to waste. For every problem there is a solution, help or patch (smile).

  4. Richard Rust

    Have Organic Brain Syndrome and TBI and I can’t think of Anything better than smoking a Joint ; usually stops Me from having aura’s an totally helps Me deal with the Life I’m stuck living now if the Veterans Administration
    would go by fact and make some changes Instead of ignoring Us or think
    We’re just making this All up to collect a Disability check !!!

    1. I believe current research is proving the casual and direct effects of cannabis are beneficial. It’s way past time that the people in charge of our government relax. Maybe they should smoke a Ganga stick or two.

  5. Josef Hlásný

    WHY a cannabis medications may slow progression of Alzheimer’s disease?
    See the abstract entitled „Neurodegenerative Diseases and Schizophrenia as a Hyper or Hypofunction of the NMDA Receptors“ presented at „29th World Veterinary Congress“ (Vancouver, 2008), by Josef Hlasny, Czech Republic;
    Neurodegenerative diseases, including BSE, Alzheimer’s disease etc. are caused by different mechanisms but may share a final common pathway to neuronal injury due to the overstimulation of glutamate receptors, especially of the N-methyl-D-aspartate (NMDA) receptor subtype. It is generally accepted that the influx of Ca2+ as a result of excessive activation of the NMDA receptor underlies the toxic actions of glutamate in many systems. Also, ammonia intoxication leads to excessive activation of NMDA receptors in brain. On the other hand, Mg2+ competes with Ca2+ at voltage-gated calcium channels both intracellularly and on the cell surface membrane. So, Mg2+ can protect against NMDA-induced neurodegeneration and Ca2+ deficiency can be important about NMDA hypofunction” in schizophrenia. In addition there can be another example about hypoglutamatergic condition; cannabinoids are known to inhibit Ca2+ channels-glutamate release in schizophrenia, and to inhibit progression of certain neurodegenerative diseases.
    There are no scientific references to date in which high intake of crude protein (and potassium) high enough to lead to a state of hyperammonemia (and hypomagnesemia) during the incubation period of the BSE. Therefore there is the first idea of this review; to show the hypomagnesemia plus hyperammonemia ‘simultaneous’ action on the ruminant tissues. So, the various clinical symptoms can be observed because the nervous system controlling both voluntary and involuntary muscles is affected (Mg and Ca disturbances). If the BSE is involved; a longer chronic action of corresponding biochemical changes in the blood (CSF) is necessary to rise irreversible neurodegenerative changes.
    So, I will perform some interpretations about this connection and some details will be presented to the Congress, and also second idea of this review; to show that cannabis use can be a proof about the link between the NMDA receptor hyperfunction (neurodegeneration) and hypofunction (schizophrenia).
    In addition to this abstract;
    1. Synaptic NMDAR activation is neuroprotective, whereas extrasynaptic NMDA receptors trigger neuronal death and/or neurodegenerative processes.
    2. Altered neuronal calcium homeostasis affects metabolism of amyloid precursor protein (APP), leading to increased production of ß-amyloid (Aß), and contributing to the initiation of Alzheimer’s disease (AD).
    3.Chronic activation of extrasynaptic NMDAR promotes leading to neuronal Aß release, representing a causal risk factor for developing AD.
    4. Reduction of extrasynaptic activity by memantine, a non-competitive NMDAR antagonist, halts Aß-induced neurotoxicity.

  6. Yes thank you very much. It was very informative and helpful as I try to understand Cannabis better.

  7. Lucia helena Medeiros

    muito bom todos os artigos científicos que vcs publicam. me ajudam muito a esclarecer axé pessoas.obrigada

  8. Jean Bonnez

    The med prescribed by most doctors for Alzheimer is Donepesil (Aricept).

    It is proven to be hardly better than a placebo, plus, there is big side effects associated with the drug.

    It gives the ”family” the ”feeling” that something is ”done” for the loved one.

    Knowing the virtues of cannabis oil and knowing that it is non toxic… i feel bad for the uninformed.

    Big Pharma is big and mui powerful…Sad…

Leave a Comment

Your email address will not be published. Required fields are marked *

Author and reviewer

  • Profile-image

    Sensi Seeds

    The Sensi Seeds Editorial team has been built throughout our more than 30 years of existence. Our writers and editors include botanists, medical and legal experts as well as renown activists the world over including Lester Grinspoon, Micha Knodt, Robert Connell Clarke, Maurice Veldman, Sebastian Maríncolo, James Burton and Seshata.
    More about this author
  • Sanjai_Sinha

    Sanjai Sinha

    Dr Sanjai Sinha is an academic faculty member at Weill Cornell Medicine in New York. He spends his time seeing patients, teaching residents and medical students, and doing health services research. He enjoys patient education and practicing evidence-based medicine. His strong interest in medical review comes from these passions.
    More about this reviewer
Scroll to Top